{"schema_version":"secwatch.filing_event.v1","accession":"0001384101-26-000012","form_type":"8-K","ticker":"VCYT","cik":"0001384101","company_name":"VERACYTE, INC.","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.958266+00:00","generated_at":"2026-05-15T11:29:18.920815+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Veracyte appoints Kevin Haas as Chief Development & Technology Officer, effective March 24, 2026","bullets":["Dr. Kevin Haas, formerly CTO of Myriad Genetics (NASDAQ: MYGN), joins as Chief Development and Technology Officer.","Compensation includes $500,000 base salary, 55% target bonus, RSUs and PSUs each valued at $1.5 million.","RSU vests over four years; PSU vests upon achievement of performance objectives set by Compensation Committee.","No family relationships or material transactions with the company or its other officers disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001384101-26-000012","json":"https://secwatch.observer/filing/0001384101-26-000012.json","markdown":"https://secwatch.observer/filing/0001384101-26-000012.md","text":"https://secwatch.observer/filing/0001384101-26-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1384101/000138410126000012/0001384101-26-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1384101/000138410126000012/vcyt-20260313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:29:18.920815+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}